53
Participants
Start Date
August 27, 2019
Primary Completion Date
June 23, 2021
Study Completion Date
June 23, 2021
APL-2
Complement (C3) Inhibitor
St. Lukes Medical Centre, Quezon City
Makati Medical Centre, Makati City
The Medical City, Pasig
Baguio General Hospital, Benguet
Mary Mediatrix Medical Center, Lipa City
Perpetual Succour Hospital, Cebu City
Ramathibodi Hospital, Bangkok
Siriraj Hospital, Bangkok
Thammasat University Hospital, Pathum Thani
Hospital Nacional Dos de Mayo, Lima
Hospital Cayetano Heredia, Jesús María
Hospital Cayetano Heredia, San Martín de Porres
Srinagaring Hospital, Khon Kaen
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai
University Malaya Medical Centre, Kuala Lumpur
Hospital Ampang, Ampang
Songklanagaring Hospital, Songkhla
Singapore General Hospital (SGH), Singapore
Research Center of the Colombian Clinical Life Cancer Foundation, Medellín
Julian Coronel Medical Center, Santiago de Cali
Queen Mary Hospital, Hong Kong
Princess Margaret Hospital, Kwai Chung
Prince and Wales Hospital, Shatin
Hospital Universitario Dr.Jose Eleuterio Gonzalez, Monterrey
Clinical Centre of Serbia, Belgrade
Hospital for Tropical disease, Bangkok
Phramongkutklao Hospital, Bangkok
Independent Public Clinical Hospital, Lubin
Institute of Hematology and Transfusiology, Warsaw
EMC Medical Institute, Wroclaw
Lead Sponsor
Apellis Pharmaceuticals, Inc.
INDUSTRY